Trial Profile
A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naive Adult Subjects.
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 19 Nov 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms FLAMINGO
- Sponsors ViiV Healthcare
- 08 Oct 2020 Results of pooled analysis assessing the efficacy and safety profile of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) relative to comparator ART in PLWH naive to ART by age group from four phase III/IIIb, presented at the 15th International Congress on Drug Therapy and HIV Infection
- 26 May 2017 Status changed from active, no longer recruiting to completed.
- 22 Jul 2015 Pooled subgroup analysis, results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.